4 2021 с обл

ONCOLOGY
BULLETIN
OF THE VOLGA REGION Vol. 12, no. 4. 2021
62. Champiat S., Dercle L., Ammari S. et al. Hyperprogressive
disease is a new pattern of progression in cancer
patients treated by anti-PD-1/PD-L1 // Clin. Cancer
Res. — 2017. — 23. — P. 1920-1928.
63. Danilova L., Wang H., Sunshine J. et al. Association of
PD-1/PD-L axis expression with cyactivity, mutational
load, and prognosis in melanoma and other solid
tumors // Proc. Natl. Acad. Sci USA. — 2016. —
113. — P. E7769-E7777.
64. Rodriguez-Vida A., Strijbos M., Hutson T. Predictive
and prognostic biomarkers of targeted agents and
modern immunotherapy in renal cell carcinoma //
ESMO Open. — 2016. — 1. — P. e000013.
65. Choueiri T.K., Halabi S., Sanford B.L. et al. Cabozantinib
versus sunitinib as initial targeted therapy for patients
with metastatic renal cell carcinoma of poor or
intermediate risk: The Alliance A031203 CABOSUN
trial // J. Clin. Oncol. — 2017. — 35. — P. 591-597.
66. Escudier B., Tannir N.M., McDermott D.F. et al.
CheckMate 214: Efficacy and safety of nivolumab
1 ipilimumab (N1I) v sunitinib (S) for treatment-native
advanced or metastatic renal cell carcinoma (mRCC),
including IMDC risk and PD-L1 expression subgroups //
Abstract (LBA5) presented at Annual Congress of the
European Society for Medical Oncology; September
8–12, 2017; Madrid, Spain.
67. Chen D.S., Mellman I. Elements of cancer immunity
and the cancer-immune set point // Nature. —
2017. — 541. — P. 321-330.
68. Kwilas A.R., Ardiani A., Donahue R.N. et al. Dual effects
of a targeted small-molecule inhibitor (cabozantinib)
on immune-mediated killing of tumor cells and
immune tumor microenvironment permissiveness
when combined with a cancer vaccine // J. Transl.
Med. — 2014. — 12. — P. 294.
69. Ozao-Choy J., Ma G., Kao J. et al. The novel role of tyrosine
kinase inhibitor in the reversal of immune suppression
and modulation of tumor microenvironment for
immune-based cancer therapies // Cancer Res. —
2009. — 69. — P. 2514-2522.
70. Tong C.C., Ko E.C., Sung M.W. et al. Phase II trial of
concurrent sunitinib and image-guided radiotherapy
for oligometastases // PLoS One. — 2012. — 7. —
P. e36979.
71. Stehle F., Schulz K., Fahldieck C. et al. Reduced
immunosuppressive properties of axitinib in
comparison with other tyrosine kinase inhibitors //
J. Biol. Chem. — 2013. — 288. — P. 16334-16347.
72. Desar I.M., Jacobs J.H., Hulsbergen-vandeKaa C.A.
et al. Sorafenib reduces the percentage of tumour
infiltrating regulatory T cells in renal cell carcinoma
patients // Int. J. Cancer. — 2011. — 129. — P. 507-512.
73. Xin H., Zhang C., Herrmann A. et al. Sunitinib inhibition
of Stat3 induces renal cell carcinoma tumor cell
apoptosis and reduces immunosuppressive cells //
Cancer Res. — 2009. — 69. — P. 2506-2513.
74. Patnaik A., Swanson K.D., Csizmadia E. et al.
Cabozantinib eradicates advanced murine prostate
cancer by activating antitumor innate immunity //
Cancer Discov. — 2017. — 7. — P. 750-765.
75. Heine A., Held S.A., Daecke S.N. et al. The VEGFreceptor
inhibitor axitinib impairs dendritic cell
phenotype and function // PLoS One. — 2015. —
10. — P. e0128897.
76. Du Four S., Maenhout S.K., De Pierre K. et al. Axitinib
increases the infiltration of immune cells and
reduces the suppressive capacity of monocytic
MDSCs in an intracranial mouse melanoma model //
Oncoimmunology. — 2015. — 4. — P. e998107.
77. Draghiciu O., Nijman H.W., Hoogeboom B.N. et al.
Sunitinib depletes myeloid-derived suppressor cells
and synergizes with a cancer vaccine to enhance
antigen-specific immune responses and tumor
eradication // Oncoimmunology. — 2015. — 4. —
P. e989764.
78. Morelli M.B., Amantini C., Santoni M. et al. Axitinib
induces DNA damage response leading to
senescence, mitotic catastrophe, and increased NK
cell recognition in human renal carcinoma cells //
Oncotarget. — 2015. — 6. — P. 36245-36259.
79. Apolo A.B., Mortazavi A., Stein M.N. et al. A phase I
study of cabozantinib plus nivolumab (CaboNivo)
and ipilimumab (CaboNivoIpi) in patients (pts) with
refractory metastatic urothelial carcinoma (mUC) and
other genitourinary (GU) tumors // Abstract (293) and
poster (E6) presented at the Annual Genitourinary
Cancers Symposium of the American Society of
Clinical Oncology; February 16–18, 2017; Orlando, FL.
80. Atkins M.B., Plimack E.R., Puzanov I. et al. Axitinib
in combination with pembrolizumab in patients
(pts) with advanced renal cell carcinoma (aRCC):
Preliminary safety and efficacy results // Ann. Oncol.
— 2016. — 27(suppl 6). — P. 773PDA.
81. Choueiri T.K., Larkin J.M.G., Oya M. et al. First-line
avelumab 1 axitinib therapy in patients (pts) with
advanced renal cell carcinoma (aRCC): Results from a
phase Ib trial // Abstract (4504) presented at theAnnual
Meeting of the American Society of Clinical Oncology;
June 2–6, 2017; Chicago, IL.
82. McDermott D.F., Atkins M.B., Motzer R.J. et al. A phase
II study of atezolizumab (atezo) with or without
bevacizumab (bev) versus sunitinib (sun) in untreated
metastatic renal cell carcinoma (mRCC) patients (pts) //
Abstract (431) presented at Annual Genitourinary
Cancers Symposium of the American Society of
Clinical Oncology; February 16–18, 2017; Orlando, FL.
83. Chowdhury S., McDermott D.F., Voss M.H. et al.
A phase I/II study to assess the safety and efficacy
of pazopanib (PAZ) and pembrolizumab (PEM) in
patients (pts) with advanced renal cell carcinoma
(aRCC) // Abstract (4506) presented at the Annual
Meeting of the American Society of Clinical Oncology;
June 2–7, 2017; Chicago, IL. 2017.
84. Amin A., Plimack E.R., Infante J.R. et al. Nivolumab (N)
(Anti-PD-1; BMS-936558, ONO-4538) in combination
with sunitinib or pazopanib in patients (pts) with
metastatic renal cell carcinoma (mRCC) // Abstract and
poster (1052PD) presented at the Annual Congress
of the European Society for Medical Oncology;
September 26–30, 2014; Madrid, Spain.
Literature review
51